Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
Investors looking for stocks that can make dramatic moves in short time frames recently got what they were looking for from Invivyd (NASDAQ: IVVD). Shares of the clinical-stage biotech stock more than doubled overnight after the company reported successful results from a late-stage clinical trial with an experimental COVID-19 prophylactic.
Is there more fuel in Invivyd's tank that can drive the stock higher?
On Dec. 18, Invivyd stock gained more than 150% after the company announced positive data from a phase 3 trial investigating VYD222 for the prevention of COVID-19. In the ongoing study, immunocompromised patients given an infusion of VYD222 produced high levels of serum virus-neutralizing antibodies (sVNA) against the omicron subvariant XBB.1.5.
Source Fool.com
